Eurizon Capital SGR S.p.A. Purchases New Position in DexCom, Inc. $DXCM

Eurizon Capital SGR S.p.A. purchased a new stake in shares of DexCom, Inc. (NASDAQ:DXCM) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 48,636 shares of the medical device company’s stock, valued at approximately $3,231,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. increased its position in shares of DexCom by 2.3% during the third quarter. Vanguard Group Inc. now owns 49,456,043 shares of the medical device company’s stock valued at $3,327,897,000 after acquiring an additional 1,133,638 shares in the last quarter. Geode Capital Management LLC increased its position in shares of DexCom by 0.4% during the fourth quarter. Geode Capital Management LLC now owns 11,006,183 shares of the medical device company’s stock valued at $727,842,000 after acquiring an additional 42,411 shares in the last quarter. CIBC Private Wealth Group LLC increased its position in shares of DexCom by 374.3% during the third quarter. CIBC Private Wealth Group LLC now owns 2,907,801 shares of the medical device company’s stock valued at $195,666,000 after acquiring an additional 2,294,709 shares in the last quarter. Legal & General Group Plc increased its position in shares of DexCom by 4.7% during the third quarter. Legal & General Group Plc now owns 2,635,700 shares of the medical device company’s stock valued at $177,356,000 after acquiring an additional 117,493 shares in the last quarter. Finally, Holocene Advisors LP bought a new stake in shares of DexCom during the third quarter valued at approximately $163,964,000. Institutional investors own 97.75% of the company’s stock.

Insider Activity

In other news, insider Kevin R. Sayer sold 26,759 shares of the business’s stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $72.00, for a total transaction of $1,926,648.00. Following the completion of the sale, the insider owned 382,482 shares of the company’s stock, valued at $27,538,704. The trade was a 6.54% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bridgette P. Heller sold 1,012 shares of the business’s stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $60.01, for a total transaction of $60,730.12. Following the sale, the director directly owned 25,007 shares of the company’s stock, valued at approximately $1,500,670.07. The trade was a 3.89% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 32,871 shares of company stock valued at $2,306,638 in the last 90 days. Company insiders own 0.28% of the company’s stock.

DexCom Trading Up 1.5%

Shares of DXCM stock opened at $74.87 on Tuesday. DexCom, Inc. has a 1 year low of $54.11 and a 1 year high of $89.98. The firm has a fifty day moving average price of $64.32 and a 200-day moving average price of $66.64. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.95 and a quick ratio of 1.64. The company has a market cap of $28.89 billion, a price-to-earnings ratio of 32.00, a PEG ratio of 1.22 and a beta of 1.45.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, April 30th. The medical device company reported $0.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.47 by $0.09. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The firm had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.17 billion. During the same quarter in the previous year, the firm posted $0.32 EPS. The company’s revenue for the quarter was up 15.0% compared to the same quarter last year. As a group, equities analysts predict that DexCom, Inc. will post 2.57 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on DXCM shares. Weiss Ratings raised shares of DexCom from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, March 4th. TD Cowen reduced their price target on shares of DexCom from $84.00 to $75.00 and set a “buy” rating for the company in a research report on Friday, May 1st. Citigroup reissued a “buy” rating and set a $84.00 price target (up from $79.00) on shares of DexCom in a research report on Thursday. Wall Street Zen downgraded shares of DexCom from a “strong-buy” rating to a “buy” rating in a research report on Sunday, May 10th. Finally, Truist Financial reaffirmed a “buy” rating and issued a $80.00 target price (down from $82.00) on shares of DexCom in a research report on Tuesday, February 17th. Three research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $82.42.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.